.
MergerLinks Header Logo

New Deal


Announced

Recro Pharma to acquire IRISYS for c.$50m.

Financials

Edit Data
Transaction Value£36m
Consideration TypeOrdinary Shares, Cash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Biotechnology

Acquisition

Single Bidder

Domestic

Private

Friendly

Majority

contract development and manufacturing organization

Pending

Synopsis

Edit

Recro Pharma, a contract development and manufacturing organization, agreed to acquire IRISYS, a provider of contract pharmaceutical product development and manufacturing services, for c.$50m. “Adding the personnel, facilities, capabilities and global customer base of IRISYS advances each of these goals and positions Recro for sustainable, profitable growth moving forward. We welcome the members of the IRISYS team to the Recro family and are eager to begin implementing the integration of the companies,” David Enloe, Recro President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US